MOTS-c FDA Status: Approval and Compounding Rules

If patients ask your practice about MOTS-c, start with its approval status. Then explain what the compounding record says. An entry in Appendix A is not an FDA drug approval.

Keep the date attached to that answer. This page reflects the regulatory record checked on November 4, 2026. Your practice should review the current documents before acting on a headline or changing its patient-facing language.

Is MOTS-c FDA approved?

No, MOTS-c is not FDA-approved: a Drugs@FDA search on November 4, 2026 returned no application listing MOTS-c as an active ingredient.

The search checked active ingredients beginning with “mots” and returned no matches. That absence check addresses approval status. It does not replace a review of the separate compounding policy and its conditions.

The HHS policy covers peptide bulk drug substances that are not components of an FDA-approved drug product. They also are not the subject of an applicable USP or NF monograph and are not on the 503A bulks list. Keep those distinctions clear when explaining the record to your team.

What changed for MOTS-c in 2026?

MOTS-c left category 2, received differing FDA staff and committee recommendations, and appeared in the October HHS draft policy.

HHS records its category 2 period as September 29, 2023 through April 22, 2026. FDA's bulk substance safety record (opens in a new tab) places MOTS-c among previously listed substances whose nominations were withdrawn. HHS says neither placement nor removal changed its status under section 503A.

The July advisory committee meeting (opens in a new tab) reviewed MOTS-c for the 503A bulks list. The FDA briefing on MOTS-c (opens in a new tab) proposed against including either MOTS-c free base or MOTS-c acetate. HHS records that CDER recommended against both forms while the committee voted in favor of both. Advisory committee recommendations are non-binding.

On October 30, 2026, HHS published notice of its draft enforcement discretion policy. Under its conditions, HHS states that it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with an Appendix A peptide.

What does the HHS draft policy mean for MOTS-c?

The draft describes conditional enforcement discretion for MOTS-c, not FDA approval.

Appendix A lists six peptides, including MOTS-c. Inclusion is only part of the review. Your practice should check the full conditions against the specific product and documentation:

• Confirm the identity and applicable limitations described in Appendix B.
• Verify that the active pharmaceutical ingredient comes from an FDA-registered facility and has a valid certificate of analysis.
• Check reporting of compounded products, serious adverse events and product quality issues to FDA and the relevant states.
• Verify the label statement: “This is a compounded drug product. Not for resale.”
• Confirm that the product contains only one active pharmaceutical ingredient listed in Appendix A.
• Check the device condition: the only delivery device co-packaged with or containing the compounded drug is an FDA 510(k)-cleared syringe.
• Verify section 503A's patient-specific prescription requirement.

The policy creates no rights and is not binding on HHS or the public. HHS may revisit it if a safety signal or product quality issue arises. The notice allowed comments for two weeks after publication under Docket No. HHS-OASH-2026-0496. Future FDA rulemaking may propose adding some or all of these peptides to the 503A bulks list.

Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness or quality before marketing. A conditional enforcement policy does not change that distinction, and a possible future rulemaking should not be described as a completed listing decision.

What has FDA said about MOTS-c safety?

FDA identifies possible immunogenicity and peptide-related impurity concerns and says it lacks important safety information about MOTS-c.

Its statement also identifies complexities in characterizing the active pharmaceutical ingredient. FDA says it has not identified human exposure data on drug products containing MOTS-c. Describe this as FDA's statement about the information it has identified, rather than a claim about every possible record.

For your practice, the distinction is straightforward: an agency statement that safety information is missing is not a safety assurance. Keep the wording tied to FDA's stated concerns and information gaps.

What about research-use-only MOTS-c?

A research-use-only label does not, by itself, settle FDA's classification of a product.

In a June 17 warning letter (opens in a new tab), FDA said “research use only” and “not for human consumption” statements did not prevent it from finding that the products were intended as drugs for human use. FDA pointed to evidence in the product labeling, including the website.

HHS says its limited policy aims to discourage widespread use of research-use-only peptides from foreign manufacturers that pose safety risks to US patients. That stated aim is separate from approval status. Your practice should not treat a research label as an answer to its regulatory questions.

What should a practice check?

Your practice should verify the applicable compounding conditions, prescription documentation, evidence for claims and state oversight before acting.

Use these questions to organize a review with your state boards and your own attorney:

• Does the documentation match the policy? Check Appendix B's identity and limitations, the certificate of analysis, labeling, reporting and the patient-specific prescription. Review the conditions together.
• What evidence supports public claims? The FTC health products guidance (opens in a new tab) says health benefit or safety claims for health-related products require competent and reliable scientific evidence. Check your proposed wording against that standard.
• Which oversight framework applies? FDA's compounding questions and answers (opens in a new tab) explain that state boards generally oversee state-licensed pharmacies day to day. FDA primarily oversees and inspects 503B outsourcing facilities, which follow current good manufacturing practice requirements. Our 503A and 503B comparison guide provides related reading.
• Is the record still current? Recheck the policy and its date before a decision. HHS may revisit its position if safety or quality issues arise. Ask your own attorney to review the current record for your practice.

Related reading

• Are Peptides Legal? FDA Status and Compounding Rules
• Telehealth Regulation News: How to Ensure Virtual Compliance
• How to Pick the Right Medical Spa Lawyer for Your Clinic
• Med Spa Laws by State: Ownership and Licensing

Sources

• HHS: Peptide Enforcement Policy and Appendices (opens in a new tab), checked November 6, 2026.
• HHS: 503A Peptide Enforcement Policy Notice (opens in a new tab), checked November 6, 2026.
• FDA: Bulk Substances With Potential Safety Risks (opens in a new tab), checked November 6, 2026.
• FDA: July 2026 Pharmacy Compounding Advisory Committee (opens in a new tab), checked November 6, 2026.
• FDA: MOTS-c Advisory Committee Briefing (opens in a new tab), checked November 6, 2026.
• FDA: June 17, 2026 Warning Letter (opens in a new tab), checked November 6, 2026.
• FTC: Health Products Compliance Guidance (opens in a new tab), checked November 6, 2026.
• FDA: Compounding and FDA Questions and Answers (opens in a new tab), checked November 6, 2026.